Accuray Incorporated (NASDAQ:ARAY) CEO Joshua Levine sold 15,839 shares of the firm’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $4.00, for a total transaction of $63,356.00. Following the completion of the transaction, the chief executive officer now directly owns 1,340,197 shares of the company’s stock, valued at approximately $5,360,788. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Joshua Levine also recently made the following trade(s):

  • On Monday, November 5th, Joshua Levine purchased 25,000 shares of Accuray stock. The stock was bought at an average cost of $4.75 per share, with a total value of $118,750.00.
  • On Wednesday, October 31st, Joshua Levine sold 18,742 shares of Accuray stock. The stock was sold at an average price of $4.69, for a total transaction of $87,899.98.
  • On Wednesday, October 3rd, Joshua Levine sold 17,242 shares of Accuray stock. The stock was sold at an average price of $4.38, for a total transaction of $75,519.96.

Shares of Accuray stock traded down $0.04 during trading on Thursday, hitting $3.93. 870,073 shares of the company’s stock were exchanged, compared to its average volume of 737,707. The company has a debt-to-equity ratio of 2.74, a current ratio of 1.69 and a quick ratio of 0.96. Accuray Incorporated has a 52-week low of $3.20 and a 52-week high of $6.15. The stock has a market cap of $344.04 million, a PE ratio of -14.04 and a beta of 1.51.

Accuray (NASDAQ:ARAY) last issued its earnings results on Tuesday, October 30th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). Accuray had a negative return on equity of 42.24% and a negative net margin of 5.79%. The business had revenue of $95.83 million for the quarter, compared to analysts’ expectations of $95.10 million. During the same period last year, the business earned ($0.11) EPS. As a group, equities analysts expect that Accuray Incorporated will post -0.14 EPS for the current year.

Several institutional investors have recently modified their holdings of ARAY. First Trust Advisors LP raised its holdings in shares of Accuray by 113.1% during the second quarter. First Trust Advisors LP now owns 27,337 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 14,508 shares during the last quarter. KBC Group NV purchased a new position in shares of Accuray during the second quarter worth $112,000. Mackay Shields LLC raised its holdings in shares of Accuray by 59.9% during the second quarter. Mackay Shields LLC now owns 264,500 shares of the medical equipment provider’s stock worth $1,084,000 after purchasing an additional 99,100 shares during the last quarter. Systematic Financial Management LP purchased a new position in shares of Accuray during the second quarter worth $1,064,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Accuray by 17.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 532,195 shares of the medical equipment provider’s stock worth $2,182,000 after purchasing an additional 78,870 shares during the last quarter. 84.28% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have issued reports on ARAY. Citigroup raised shares of Accuray from a “sell” rating to a “neutral” rating and raised their price target for the stock from $3.50 to $3.90 in a report on Thursday, November 1st. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a report on Wednesday, August 22nd. Jefferies Financial Group reissued a “buy” rating and set a $6.00 target price on shares of Accuray in a report on Friday, August 17th. Finally, BidaskClub cut shares of Accuray from a “sell” rating to a “strong sell” rating in a report on Friday, August 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Accuray presently has a consensus rating of “Hold” and a consensus target price of $5.63.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/accuray-incorporated-aray-ceo-sells-63356-00-in-stock/2665921.html.

Accuray Company Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Further Reading: What is a conference call?

Insider Buying and Selling by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.